dc.description |
Department of Pharmacology and
Clinical Pharmacy, Nicolae Testemitanu State University of Medicine and Pharmacy,
Chisinau, Republic of Moldova, The 8th International Medical Congress for Students and Young Doctors, September 24-26, 2020 |
en_US |
dc.description.abstract |
Introduction. Migraine is the most common neurological disorder, affecting about 12-15% of
people. In R. Moldova, migraine occurs in about 10% of the population, most commonly
among women in the age group from 20 to 35 years. Migraine has an ancient history, being
known since Neolithic. However, it is surprising that the effective anti-migraine drugs have,
until recently, been limited in number. Only in recent decades, great steps have been taken in
the development of anti-migraine drugs.
Aim of study. To determine the clinical features of migraine and its treatment methods.
Materials and methods. The study of clinical cases with migraine was carried out during the
period 2019-2020 in hospitals and in the community pharmacies, with 133 research subjects,
28-55 years old.
Results. From the total number of investigated 133 patients, 36 were women (58.1%) with a
mean age of 41 years old. 47.3% patients showed the presence of migraine without aura and
22.7% - migraine with aura, 11.5% had rare episodic migraine, 48.3% - frequent episodic
migraine, and 29.2% - chronic migraine. The study determined that patients suffered more than
5 attacks in 84% of cases. moderate or severe pain intensity in 73% of patients and associated
symptoms, such as nausea and/or vomiting; photophobia and phonophobia in 67% of patients.
Analgesics are the medication of choice in the treatment of mild-moderate migraine attacks,
with administration of ibuprofen 200-800 mg (37%) and of preparations with the fixed
combination of acetylsalicylic acid, paracetamol, peopiphenazone, ergotamine, caffeine etc.,
such as: Nomigren, Migretil, Antinevralgic, which are more effective in the treatment of acute
migraine than each compound separately. The hospital treatment includes reduced number of
specific preparations for migraine, but are present drugs from various pharmacological groups,
with nootropic, cerebroprotective, anxiolytic and antidepressant actions. This fact can be
explained by the presence of comorbidities in association with the migraine attacks, which
requires complex neurological treatment and not just the specific antimigrenous one.
Conclusions. In light-medium migraine pharmacotherapy, simple analgesics, such as
ibuprofen and paracetamol, are recommended, combined with the fixed association antimigraine
drugs, anti-emetics and avoidance of triggering factors. In the hospital treatment of
migraine are administered preparations from various pharmacological groups with nootropic,
cerebroprotective, anxiolytic and antidepressant actions, for the purpose of treatment and
comorbidities. |
en_US |